Literature DB >> 10329600

Decreased proliferation and altered differentiation in osteoblasts from genetically and clinically distinct craniosynostotic disorders.

A Fragale1, M Tartaglia, S Bernardini, A M Di Stasi, C Di Rocco, F Velardi, A Teti, P A Battaglia, S Migliaccio.   

Abstract

Craniosynostoses are a heterogeneous group of disorders characterized by premature fusion of cranial sutures. Mutations in fibroblast growth factor receptors (FGFRs) have been associated with a number of such conditions. Nevertheless, the cellular mechanism(s) involved remain unknown. We analyzed cell proliferation and differentiation in osteoblasts obtained from patients with three genetically and clinically distinct craniosynostoses: Pfeiffer syndrome carrying the FGFR2 C342R substitution, Apert syndrome with FGFR2 P253R change, and a nonsyndromic craniosynostosis without FGFR canonic mutations, as compared with control osteoblasts. Osteoblasts from craniosynostotic patients exhibited a lower proliferation rate than control osteoblasts. P253R and nonsyndromic craniosynostosis osteoblasts showed a marked differentiated phenotype, characterized by high alkaline phosphatase activity, increased mineralization and expression of noncollagenous matrix proteins, associated with high expression and activation of protein kinase Calpha and protein kinase Cepsilon isoenzymes. By contrast, the low proliferation rate of C342R osteoblasts was not associated with a differentiated phenotype. Although they showed higher alkaline phosphatase activity than control, C342R osteoblasts failed to mineralize and expressed low levels of osteopontin and osteonectin and high protein kinase Czeta levels. Stimulation of proliferation and inhibition of differentiation were observed in all cultures on FGF2 treatment. Our results suggest that an anticipated proliferative/differentiative switch, associated with alterations of the FGFR transduction pathways, could be the causative common feature in craniosynostosis and that mutations in distinct FGFR2 domains are associated with an in vitro heterogeneous differentiative phenotype.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10329600      PMCID: PMC1866602          DOI: 10.1016/S0002-9440(10)65401-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  46 in total

1.  Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis gyrata syndrome.

Authors:  K A Przylepa; W Paznekas; M Zhang; M Golabi; W Bias; M J Bamshad; J C Carey; B D Hall; R Stevenson; S Orlow; M M Cohen; E W Jabs
Journal:  Nat Genet       Date:  1996-08       Impact factor: 38.330

2.  Common mutations in the fibroblast growth factor receptor 3 (FGFR 3) gene account for achondroplasia, hypochondroplasia, and thanatophoric dwarfism.

Authors:  J Bonaventure; F Rousseau; L Legeai-Mallet; M Le Merrer; A Munnich; P Maroteaux
Journal:  Am J Med Genet       Date:  1996-05-03

Review 3.  Fibroblast growth factors and their receptors: an information network controlling tissue growth, morphogenesis and repair.

Authors:  D G Fernig; J T Gallagher
Journal:  Prog Growth Factor Res       Date:  1994

Review 4.  Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype.

Authors:  G S Stein; J B Lian
Journal:  Endocr Rev       Date:  1993-08       Impact factor: 19.871

Review 5.  Transcriptional control of osteoblast growth and differentiation.

Authors:  G S Stein; J B Lian; J L Stein; A J Van Wijnen; M Montecino
Journal:  Physiol Rev       Date:  1996-04       Impact factor: 37.312

6.  Antisera and cDNA probes to human and certain animal model bone matrix noncollagenous proteins.

Authors:  L W Fisher; J T Stubbs; M F Young
Journal:  Acta Orthop Scand Suppl       Date:  1995-10

7.  Acidic fibroblast growth factor inhibits osteoblast differentiation in vitro: altered expression of collagenase, cell growth-related, and mineralization-associated genes.

Authors:  K T Tang; C Capparelli; J L Stein; G S Stein; J B Lian; A C Huber; L E Braverman; W J DeVito
Journal:  J Cell Biochem       Date:  1996-04       Impact factor: 4.429

8.  Constitutive activation of fibroblast growth factor receptor-2 by a point mutation associated with Crouzon syndrome.

Authors:  K M Neilson; R E Friesel
Journal:  J Biol Chem       Date:  1995-11-03       Impact factor: 5.157

9.  Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome.

Authors:  A O Wilkie; S F Slaney; M Oldridge; M D Poole; G J Ashworth; A D Hockley; R D Hayward; D J David; L J Pulleyn; P Rutland
Journal:  Nat Genet       Date:  1995-02       Impact factor: 38.330

10.  Endogenous protein kinase-C activation in osteoblast-like cells modulates responsiveness to estrogen and estrogen receptor levels.

Authors:  S Migliaccio; W C Wetsel; W M Fox; T F Washburn; K S Korach
Journal:  Mol Endocrinol       Date:  1993-09
View more
  22 in total

1.  In vivo modulation of FGF biological activity alters cranial suture fate.

Authors:  J A Greenwald; B J Mehrara; J A Spector; S M Warren; P J Fagenholz; L E Smith; P J Bouletreau; F E Crisera; H Ueno; M T Longaker
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

2.  Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells.

Authors:  Emilia Stellacci; Antonella Di Noia; Angela Di Baldassarre; Giovanni Migliaccio; Angela Battistini; Anna Rita Migliaccio
Journal:  Exp Hematol       Date:  2009-05       Impact factor: 3.084

Review 3.  Gene expression profiling in human craniosynostoses: a tool to investigate the molecular basis of suture ossification.

Authors:  Camilla Bernardini; Marta Barba; Gianpiero Tamburrini; Luca Massimi; Concezio Di Rocco; Fabrizio Michetti; Wanda Lattanzi
Journal:  Childs Nerv Syst       Date:  2012-08-08       Impact factor: 1.475

Review 4.  The molecular and cellular basis of Apert syndrome.

Authors:  Chao Liu; Yazhou Cui; Jing Luan; Xiaoyan Zhou; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2013-11

5.  Novel pHEMA-gelatin SPHs as bone scaffolds in dynamic cultures.

Authors:  Damla Cetin; A Sera Kahraman; Menemşe Gümüşderelioğlu
Journal:  J Mater Sci Mater Med       Date:  2012-08-08       Impact factor: 3.896

6.  Osteoblast differentiation profiles define sex specific gene expression patterns in craniosynostosis.

Authors:  Sarah S Park; Richard P Beyer; Matthew D Smyth; Christine M Clarke; Andrew E Timms; Theo K Bammler; Brendan D Stamper; Brigham H Mecham; Jennifer A Gustafson; Michael L Cunningham
Journal:  Bone       Date:  2015-03-07       Impact factor: 4.398

7.  Postnatal brain and skull growth in an Apert syndrome mouse model.

Authors:  Cheryl A Hill; Neus Martínez-Abadías; Susan M Motch; Jordan R Austin; Yingli Wang; Ethylin Wang Jabs; Joan T Richtsmeier; Kristina Aldridge
Journal:  Am J Med Genet A       Date:  2013-03-12       Impact factor: 2.802

8.  Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+P253R) mice.

Authors:  Yingli Wang; Miao Sun; Victoria L Uhlhorn; Xueyan Zhou; Inga Peter; Neus Martinez-Abadias; Cheryl A Hill; Christopher J Percival; Joan T Richtsmeier; David L Huso; Ethylin Wang Jabs
Journal:  BMC Dev Biol       Date:  2010-02-22       Impact factor: 1.978

9.  Further analysis of the Crouzon mouse: effects of the FGFR2(C342Y) mutation are cranial bone-dependent.

Authors:  Jin Liu; Hwa Kyung Nam; Estee Wang; Nan E Hatch
Journal:  Calcif Tissue Int       Date:  2013-01-29       Impact factor: 4.333

Review 10.  Understanding craniosynostosis as a growth disorder.

Authors:  Kevin Flaherty; Nandini Singh; Joan T Richtsmeier
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2016-03-22       Impact factor: 5.814

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.